We reduce our earnings estimate by 3%/6% for FY22/23E, as we trim our growth projection for selective countries in branded and generic export formulation segment. 3QFY21 revenue was in-line with our estimate, however there was an EBITDAM beat of 250bps due to continued lower marketing expense. IPCA reaffirmed its growth guidance for FY22-23E with 1) India...